Core Insights - BetterLife Pharma Inc. is advancing the development of BETR-001, a non-hallucinogenic derivative of LSD, targeting Traumatic Brain Injury (TBI), cluster headaches, and migraines [1][3] - Daniel Carcillo, a former NHL player and advocate for TBI survivors, joins BetterLife as a Corporate Advisor to enhance the development of BETR-001 [2][3] - BETR-001 is currently in preclinical and IND-enabling studies, with a unique position as an unregulated substance that can be self-administered [3] Company Overview - BetterLife Pharma Inc. focuses on developing and commercializing BETR-001 for various neurological disorders, with a synthesis patent that eliminates regulatory hurdles [3] - The company also possesses a drug candidate aimed at treating viral infections and is exploring strategic alternatives for its further development [4]